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1 Introduction 
The field of asymmetric synthesis is at an important cross-
roads currently. With both overall efficiency and control 
of stereochemistry being at a premium, organic chem-
ists are active at the frontiers of methodology develop-
ment, both on the more traditional organic/organome-
tallic front, and now also on the biocatalytic front. In the 
former area, exciting developments include recent ad-
vances in organocatalysis[1] and base metal catalysis.[2] In 
the latter, the number and scope of enzymatic transfor-
mations continues to expand, particularly with advances 
in the directed evolution of protein catalysts in “the third 
wave of biocatalysis.”[3] 
The time is now ripe for academic and process chemists 
to meld frontline synthetic organic methods with state-
of-the-art biocatalytic methods. Indeed, over the past de-
cade or so, in the domain of process chemistry partic-
ularly, one can see a clear evolution of thinking in this 
direction. Examples include the synthesis of pregabalin 
(Lyrica™), the first generation synthesis of which involved 
catalytic asymmetric hydrogenation, and the streamlined 
synthesis of which involves kinetic resolution with a lipase.
[4] For the synthesis of atorvastatin (Lipitor™), hybrid syn-
thetic organic/ enzymatic approaches have been taken, 
wherein a dehydrogenase sets the stereochemistry of the 
side chain.[5] In streamlining process chemistry routes into 
a sister-statin; namely rosuvastatin (Crestor™), advantage 
has been taken of the power of aldolase technology.[6] 
Most recently, for the other major, natural product-derived 
statin category, simvastatin can now be synthesized bio-
catalytically by means of an evolved “simvastatin synthase” 
enzyme, in pioneering work by Tang and co-workers.[7] 
A particularly impressive case in process circles revolves 
around the synthesis of the dipeptidyl peptidase-4 inhibi-
tor, sitagliptin (Januvia™), a useful antidiabetic agent. The 
Merck process group won two Presidential Green Chem-
istry awards for distinct approaches into this target. Ini-
tially, the award was given for a route involving catalytic 
asymmetric hydrogenation.[8] The second generation route 
involved extensive remodeling of a transaminase site in 
a “directed evolution” endeavor jointly with Codexis, and 
provides a beautiful hybrid organic/enzymatic route into 
this complex heterocyclic target bearing as a key core, a 
β3-aromatic amino acid.[9] 
This review will focus on a particularly auspicious area 
of biocatalysis wherein a racemic educt is effectively “de-
racemized” and two contiguous stereocenters are often 
set, in the same operation. Specifically, we will discuss dy-
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namic reductive kinetic resolution (DYRKR) involving de-
hydrogenase enzymes. It is worth noting that other en-
zyme classes, namely transaminases[10] and benzaldehyde 
lyases,[11] have recently found application in similar strat-
egies. The reader is also pointed to other reviews on de-
hydrogenase enzymes that may be of interest.[12] Our own 
interest in dehydrogenase enzymes stems from their util-
ity as “reporting enzymes” in a method for catalyst dis-
covery that we have developed known as in situ enzymatic 
screening (ISES).[13] In this approach, an alcohol dehydro-
genase (ADH) oxidizes the alcoholic product or by-prod-
uct of a reaction of interest. The concomitant increase in 
Abs340
 associated with the formation of NAD(P)H is mon-
itored spectroscopically. By utilizing two reporting ADH 
enzymes with complementary enantioselectivities, the ex-
perimentalist can glean information on relative rates and 
enantioselectivities of a series of catalysts or chiral ligands 
of interest, in a parallel screening format.[14] 
In the course of evaluating dehydrogenase “report-
ing enzymes” for their substrate specificitiy and enanti-
oselectivity, we have become very interested in also ex-
ploiting these enzymes for their potential in asymmetric 
synthesis.[15] Indeed, alcohol dehydrogenases provide a 
complementary and greener alternative to traditional 
Noyori-type asymmetric carbonyl hydrogenation, such 
as was exploited in the first generation Januvia™ syn-
thesis.[8] Furthermore, the advancement of structural bi-
ology, computational chemistry, and molecular biology 
have allowed for the fine tuning of natural ADHs to tailor 
them to substrates of interest. These advantages have led 
to dehydrogenases being the preferred catalysts for ke-
tone reductions in the Merck process group.[16,17] In fact, 
it is estimated that 10% of current drug syntheses rely 
on a biocatalytic step.[18] This underscores the need for 
the synthetic chemist to work from a set of retrosynthetic 
transformations that complements the traditional Coreye-
sque set[19] with a new set of biocatalytic transform arrows. 
Turner and co-workers refer to this complementary view 
as “biocatalytic retrosynthesis.”[20] 
Here the focus is on the synthetic exploitation of ADHs 
in dynamic kinetic resolutions. To be clear, for classical ki-
netic resolutions, in the ideal case, using a lipase, say, one 
can obtain the enantiopure acylated product in 50% yield, 
while also recovering 50% of the antipodal unreacted al-
cohol (Scheme 1, top). While it can be advantageous to 
access both enantiomeric forms of a building block,[14a] 
this is not always desirable. To address this limitation, dy-
namic kinetic resolution (DKR) may be employed, where 
the stereocenter in question can be racemized. DKR has 
seen a large increase in application over the past couple 
of decades. In contrast to traditional KR, DKR can provide 
complete converstion to enantiomerically pure product 
from racemic starting material by combining the princi-
ples of classical KR with continuous racemization of the 
unreacted enantiomer (Scheme 1, bottom). 
The racemization can be mediated by a chemical or 
biological catalyst,[21] or may even occur spontaneously 
under the reaction conditions.[21d] A successful DKR re-
quires that the rate of racemization (krac) exceed the rate 
of processing the slow enantiomer (kslow) by the catalyst 
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Scheme 1. Representative examples of KR and DKR.  
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to a variety of compound classes including alcohols,[22] 
amines,[23] cyanohydrins,[24] and amino acids.[25] 
DKR can also, of course, be extended to cases in which 
more than two antipodal products are possible as is the 
case for the lipase resolution shown above. In cases where 
a new stereogenic center is set, the process now has the 
ability of generating two stereocenters in one transfor-
mation, effectively dialing in one of four possible stereo-
isomeric products. A traditional chemo-catalytic method 
for this process is NoyoriIs Ru-catalyzed hydrogenation 
of α-substituted- β-keto esters to afford α-substituted-
β-hydroxy esters.[26] An enzymatic rival of this process 
can be achieved by a variety of alcohol dehydrogenases 
or microbes as demonstrated in Scheme 2. This process 
is termed dynamic reductive kinetic resolution (DYRKR). 
The first microbial DYRKR can be traced back to Deol in 
1976[27] by employing baker’s yeast in the reduction of the 
same compounds described in the Noyori system. The dy-
namic reductive processes that followed for the next two 
decades often employed whole cells due to availability. 
While these systems were able to achieve high enantio-
meric excesses (ee) in some cases, the issue of several ac-
tive enzymes often reduced overall success. Recent ad-
vances in molecular biology, genomic sequencing, and 
cofactor regeneration systems have allowed for the ex-
pression and isolation of individual alcohol dehydroge-
nases to overcome these earlier limitations. 
DYRKR strategies with reductive enzymes can be rep-
resented by systems as shown in Scheme 3. Adjacent to a 
carbonyl resides an epimerizable stereocenter, bearing an 
acidic proton. Under the reaction conditions, the two en-
antiomers are rapidly interconverted through an enol(ate) 
intermediate. This same principle applies to a number of 
related functionalities, including but not limited to, cyclic 
and acyclic keto phosphonates, keto sulfones, α-cyano 
ketones, and even α-alkyl aldehydes. While the reduction 
of aldehydes is not typically associated with asymmetric 
synthesis, these systems serve as an entry point into en-
antiomerically enriched α-substituted primary alcohols. 
This review will focus on the current scope of DYRKR 
and its application in both academic laboratory and the 
industrial process group settings. An effort is made to pro-
vide a thorough overview of the application of this ap-
proach to various functional groups and scaffolds, includ-
ing important synthetic and pharmaceutical targets as well 
as to offer a glimpse into future challenges for DYRKR. 
Note that through this review a grey box is used to de-
note the functionality with the substrate that allows for 
stereochemical dynamism under the reaction conditions. 
2 β-Keto Ester Reduction 
The reduction of β-keto esters represents one of the most 
important DYRKR transformations. It is possible to see 
large differences in selectivities based on the nature of 
the ester, the α-alkyl group, or the R group flanking the 
ketone. One such example is reported by Häckh in the 
reduction of 2-Me-3-oxo esters (Scheme 3).[28] Replace-
ment of an SNAC ester with an ethyl ester increased en-
antioselectivity from 43% ee to 92% ee. Interestingly, the 
same ester substitution for 2-Me-3-oxovalerate esters re-
versed the stereochemical course of the reduction from 
(2R,3R) to (2S,3S). 
While a highly selective DYRKR may “surgically” deliver 
one of four possible stereoisomeric products, inevitably, 
less selective situations are often encountered, with an 
undesired isomer also being formed. To mitigate against 
this, it may be possible to employ individual enantiocom-
plementary or diastereocomplementary enzymes. Another 
approach is to use directed evolution, by generating a li-
brary of genetically engineered mutants and selecting for 
the stereochemistry of interest. As an example of the for-
mer strategy, Lîdeke and co-workers reported the identi-
fication of enzymes that generate three of the four possi-
ble stereoisomers of 5-hydroxy-4-methyl-3-oxohexanoate.
[29] The three enzymes originate from distinct sources and 
display high enantio- and diastereoselectivities for com-
plementary products (Scheme 4). 
Scheme 2. An example of the DYRKR process. Scheme 3. Reduction of α-methyl-β-keto esters. 
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In an interesting new approach, a collaborative effort 
studied the application of six different ADHs to the re-
duction of α,α-dihaloacetophenones.[30] The initial screen 
of six dehydrogenases (ADH-A, R. ruber; RasADH, Ralsto-
nia sp.; SyADH, Sphingobium yanoikuyae; LBADH, L. bre-
vis; LKADH, L. kefir) across this family of substrates re-
vealed that five demonstrated high enantioselectivity. The 
authors also investigated the ability of these enzymes 
to distinguish halogen atoms, for example, by reducing 
α-bromo-α-chloroacetophenone (Scheme 5). Although 
diastereoselectivity was limited (59% de, ADH-A), the en-
antioselectivity remained high (99% ee). The reduction of 
α-chloro-α-fluoroacetophenone proceeded with poorer 
diastereoselectivity, perhaps as a result of the enzyme be-
ing unable to distinguish the relative orientation of the 
smaller fluorine atom when compared with the bulky bro-
mine atom. 
While many of the works highlighted in this review 
make use of whole cell or overexpressed dehydroge-
nases, Musa and Phillips demonstrated the power of ra-
tional design and site-directed mutagenesis to broaden 
the substrate scope of an enzyme. Thermoanaerobac-
ter ethanolicus secondary ADH (TeSADH) had previously 
shown synthetic utility due to its ability to stereoselectively 
operate at elevated temperatures and in an organic sol-
vent-rich milieu (30% v/v).[31] The W110A mutant not only 
reversed the enantiopreference of Thermoanerobacter eth-









pocket of the active site to accommodate bulkier aryl sub-
stitutents. Furthermore, this W110A mutant demonstrated 
the ability to catalyze the DYRKR of α-chloro ketones with 
good diastereo- and excellent enantioselectivity as shown 
in Scheme 6. The chlorohydrin was transformed into the 
corresponding epoxide. 
The diastereoselective DYRKR of various 3-ketoglu-
tarates was reported by Kambourakis and Rozzell.[32] A 
range of R groups was successfully accommodated using 
a spectrum of KREDs (Scheme 7). For example, when R=i–
Pr, KRED 101 provided the (3S,4R) product in 90% de and 
99% ee. However, KRED 108 could select for the (3R,4R) 
product in 99% de and 99% ee. Regiodivergent modifi-
cation of this common hydroxy intermediate allowed for 
the synthesis of a number of statin analogues. Further-
more, the ability of KRED 108 to select for the anti reduc-
tion product granted access to individual diastereomers 
of these statins. 
The Gotor group was able to access enantiopure 3,4-di-
hydroisocoumarins through a dynamic reductive kinetic 
resolution using ADH-A from Rhodococcus ruber.[33] Ini-
tial experiments proceeded more like classical kinetic res-
olutions. The enzymatic reaction only proceeded to ~38% 
conversion with high diastereoselectivity (99% de) and en-
antioselectivity (99% ee). However, the remaining ketone 
was also found in 60% ee. This led the investigators to add 
Et3N (1% v/v) to facilitate racemization, ultimately result-
ing in a DYRKR process that yields the (2S,3S)-alcohol in 
good yield and excellent selectivity (Scheme 8). Follow-
ing acid hydrolysis of the nitrile, lactonization ensues, pro-
viding for an elegant route into the desired dihydroiso-
comarin scaffold. 
Scheme 6. Exploitation of a useful TeSADH mutant. 
Scheme 4. Tuning 3,5-diketo ester reductions.  
Scheme 5. Reduction of α,α-dihaloacetophenones. 
Scheme 7. Access to γ-amino-β-hydroxy esters.  
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While baker’s yeast served as the workhorse in early 
efforts of microbial reductions, new organisms are con-
tinuously being evaluated for similar biotransformations. 
The search for other microbial strains harboring ADHs ca-
pable of catalyzing similar biotransformations has led to 
a number of prospecting successes.[34] A schematic map-
ping of species vs. ideal β-keto ester (nitrile) substrate type 
is presented in Scheme 9. Note the high selectivities ob-
served in these promising screens for DYRKR transforma-
tions of diverse β-keto functionalities. From these screens 
it is clear that valuable ADHs can be mined from Geotri-
chum candidum (α-alkyl-β-keto esters),[35] Rhizopus arrhi-
zus (α-cyanotetralone),[36] Mucor racemosus (cyclic β-keto 
esters),[37] and Kloeckera magna (large cyclic β-keto esters).
[37] Other fungal sources have shown promise for the re-
duction of α-alkyl-β-keto esters.[38] 
The Stewart group has reported extensively on the use 
of baker’s yeast, or the independently expressed ADH 
enzymes that comprise this sector of its genome, in the 
DYRKR of various substrates. Early efforts were made to 
develop a biocatalytic route into the phenyl isoserine 
side chain of the taxanes. One such example is the use 
of various yeast strains to reduce β-azido-α-keto esters.
[39] Although these reductions proceeded with excellent 
enantioselectivity (>98% ee) for three strains, limited dia-









communication, the authors attempted a different route 
to the side chain via DYRKR of the Ojima lactam.[40] Un-
fortunately, this process appeared to suffer in selectivity 
when conversion exceeded 50%. It was thought that the 
low diastereoselectivities could perhaps be a result of mul-
tiple enzymes acting upon the substrate. This led to the 
systematic construction of a library of 19 GST-tagged re-
ductases from the yeast genome. 
To address this shortcoming of the early attempts, Kay-
ser went on to overexpress the yeast reductase, Ara1P, in E. 
coli.[41] What is the key in this case is the importance of the 
experimental conditions. In a shake-flask, Ara1P yielded a 
1.4:1 mixture of diastereomers (both in 99% ee). However, 
under fermenting conditions, only the (3S,4R) product was 
obtained (Scheme 10). Introduction of furyl or thiophe-
nyl substituents, resulted in low diastereoselectivities, per-
haps because the reduction rates of these substrates ex-
ceed the α-center racemization rates. 
Kalaitzakis and Smonou, in a joint effort with Biocata-
lytics, systematically explored the stereo- and chemose-
lectivity of a number of ADH enzymes and applied this 
to the reduction of β-keto esters and 1,3- diones.[42] The 
next iteration employed a one-pot, two-enzyme approach 
to access 1,3-diols from 1,3-diketones.[43] As shown in 
Scheme 14, some of the examples are symmetrical dio-
nes. However, in other cases where no symmetry is pres-
ent (Scheme 11), KRED 102 has remarkable regioselectivity 
in addition to diastereo- and enantioselectivity to produce 
the l-syn-α-alkyl-β-hydroxy ketones. 
The authors do not observe any reduction to the diol 
with KRED 102 which demonstrates its ability to select ex-
clusively for the dione. The second reduction to the diol 
with either KRED 101 or A1B is also noted to be very se-
lective. Furthermore, KRED 101 and A1B display opposite 
facial selectivities, allowing for access to different 1,3-diol 
diastereomers. This represents an exciting development 
for the DYRKR-based synthesis of 1,3-diols of high opti-
cal purity and targeted stereochemistry. The authors were 
able to apply this DYRKR approach to the synthesis of a 
number of pheromones. In one case, the KRED-A1B-me-
diated reduction of methyl 2-methyl-3-oxopentanoate led 
to the stereoselective synthesis of sitophilate, a phero-
mone of the granary weevil.[44] Combining the chemose-
lectivity of KRED 102 in the reduction of 1,3-diketones 
with the stereoselectivity of KRED-B1E in the reduction 
Scheme 8. Stereocontrolled entry into 3,4-disubstituted dihy-
droisocoumarins.  
Scheme 9. Reducing selected β-keto substrate motifs with var-
ious yeast strains.  
Scheme 10. DYRKR entry into the taxane side chain. 































of β-keto esters allowed for an impressive, enzymatically 
tuned entry into the beetle pheromones, stegobiol and 
steobinone (Scheme 12).[45] 
Collaborative work by Kroutil and Gotor examined a 
large series of dehydrogenases (ADH-A, CPADH, TeSADH, 
SyADH, RasADH, LBADH, LKADH) across various combi-
nations of α-alkyl-β-keto esters.[46] These enzymes were 
grouped according to the ability to handle certain ste-
ric requirement (termed “bulky-bulky” substrates) or for 
the reduction to proceed in a Prelog or anti-Prelog fash-
ion (Scheme 13).[47] While ADH-A, CPADH, and TeSADH 
tended to favor the formation of the (2R,3S)-product when 
R=small, RasADH [(2S,3S)- leading] and SyADH [(2R,3S)-
leading] were able to accept bulkier substrates. The use 
of the anti-Prelog enzymes, LBADH and LKADH, provided 
access to the syn (2S,3R)-products. 
The reduction of cyclohexenone derivatives presents its 
own unique problem as the regio- and chemoselectivity 
of 1,2- vs. 1,4-reduction becomes a factor. Kosjek and co-
workers screened a library of KREDS against a cyclohexe-
none with a g-racemizable center (Scheme 14).[48] Under 
the reaction conditions, KRED 108 was able to reduce the 
vinylogous keto ester in high diastereoselectivity (99% de 
cis) and enantioselectivity [99% (S) with regard to the al-
cohol]. This serves as a representative example of enzymes 
being capable of distinguishing distal stereocenters in the 
enzymatic binding step. 
Another example of such distal stereo-discrimination is 
seen in the YKER-I (from baker’s yeast) reduction of sec-
alkyl 2-methyl-3-oxobutyrates.[49] The active site of YKER-I 
not only is selective for the 2Risomer but also for the 1’R-
stereochemistry (Scheme 15). The result is that the reduc-
tion proceeds to give only one of eight possible stereoiso-
meric products. The recovered ketone is found to maintain 
a high enantiomeric excess at the 1’-position. By obtain-
ing kinetic parameters for the individual 1’-enantiomers, 
Scheme 11. Setting three contiguous centers with two consec-
utive ADH-mediated reductions. 
Scheme 13. Syn-selectivity: Prelog vs. anti-Prelog ADHs. 
Scheme 14. Reduction of vinylogous keto esters. 
Scheme 12. Dual DYRKR entry into stegobiol.









the contributions of kcat
 and Km
 could be determined. 
Whereas the selectivity of lipases is often dominated by 
kcat,
[50] HLADH appears to be controlled by Km.[51] The ori-
gin for this discrimination appears to be attributed to the 
differences in binding affinity of the 1’ stereoisomers to 
YKER-I. The Km
 for the 1’R substrate was found to be 10 
times lower than that of the 1’S-isomer. 
From Stewart’s collection of expressed yeast ADHs, an 
effort was made to characterize the enzyme for the abil-
ity to selectively catalyze the reduction of various β-keto 
esters,[52] particularly, α-chloro-β-keto esters.[53] Through 
extensive characterization, multiple enzymes were found 
to catalyze the reduction of at least two of the possible di-
astereomers with excellent selectivity (Scheme 16).[53] This 
led to the synthesis of both enantiomers of the taxol side 
chain by double inversion of the α-chloro-β-hydroxy es-
ter, proceeding through an epoxide intermediate. 
Recently, in our laboratory, a dehydrogenase from Clos-
tridium acetobutylicum (CaADH) was expressed in E. coli 
and reported to be efficient on the same system. The 
CaADH reduction proceeded with excellent diastereo- 
(95% de, syn) and enantioselectivity (99% ee), even on a 
gram scale.[15b] Indeed, much more recent work indicates 
that this enzyme has enormous potential in asymmetric 
synthesis, displaying remarkable active site plasticity, while 
retaining stereochemical fidelity.[15a] 
This represents a departure from the common α-alkyl-
β-keto systems so far described. The presence of other 
α-heteroatomic functionality has been studied. In 1986, 
Sato reported the ability of baker’s yeast to catalyze the 
DYRKR of α-hydroxy-β-keto esters.[54] Substrate scope was 
limited, but high enantioselectivities were observed in three 
instances. However, the common issue of diastereoselec-
tivity persists, perhaps due to multiple active ADHs within 
the genome. This work was later expanded upon by Fad-
navis and applied to the synthesis of chiral decalactones.
[55] More recently, a panel of microbes was screened for the 
ability to selectively reduce 2-phenoxy-3-oxobutanoates.[56] 
This system maps onto that of clofibrate, a cholesterol-low-
ering compound. Adverse effects associated with clofibrate 
have driven the search for new analogues. 
While baker’s yeast was shown to reduce the butano-
ates with 92% de (syn) and 99% ee (2R,3S),[56] Kluyvero-
myces marxianus demonstrated better diastereoselectiv-
ity, providing the same product in 99% de and 97% ee 
(Scheme 17). The same group was able to isolate and 
purify the hypothesized ADH from K. marxianus and ap-
ply it to the reduction of α-(phthalamido) methyl-β-keto 
esters.[57] 
In 2013, the process group at Merck reported the selec-
tive reduction of α-amino-β-keto esters using in-house-
engineered dehydrogenases.[58] The syn amino alcohol 
was obtained in remarkable diastereo- (99% de) and en-
antioselectivity (99% ee) (Scheme 18). The amino alcohol 
was eventually transformed into cis-2,5-pyrrolidine, a core 
scaffold of β3-andrenergic receptor agonists. In this syn-
thesis, the selective bio-reduction to generate two stereo-
centers allowed for a subsequent diastereoselective hy-
drogenation to set a third stereocenter. 
3 Other β-Keto Systems 
In work that expands the DYRKR domain beyond β-keto 
esters, Delhi and Gotor explored the whole cell reduction 
of α-cyano-cyclopentanone.[59] Baker’s yeast and Saccha-
romyces montanus provided the most efficient DYRKR 
Scheme 17. Useful DYRKR activity in K. marxianus. 
Scheme 18. Toward α-amino-β-hydroxy esters. 
Scheme 15. Discriminating distal stereocenters 
Scheme 16. DYRKR of α-chloro-β-keto esters. 
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with useful selectivity (98% de and 97% ee) (Scheme 19). 
Moving to the 6-membered ring provided similar selec-
tivities. These findings allowed for the synthesis of cis-
hydroxy nitriles, as opposed to the more common trans-
diastereomers generated in the opening of epoxides or 
aziridines. 
Acyclic systems of α-cyano ketones have also been ex-
plored. The work of Itoh and co-workers demonstrated the 
ability of baker’s yeast to reduce a number of 3-oxobutyr-
onitriles (Scheme 20).[60] It is worth noting that the pres-
ence of the aryl group appears to be important in sub-
strate recognition, as replacing the aryl group with other 
alkyl chains resulted in little diastereoselectivity (<10%). 
The absolute stereochemistry of this reduction is in good 
agreement with the work of Delhi. 
Phosphonates serve as non-hydrolyzable phosphate 
surrogates that have important utility in studying signal-
ing pathways, inhibiting plant amino acid biosynthesis, 
or as reverse transcriptase inhibitors. As such, the devel-
opment of asymmetric routes to phosphonate building 
blocks will continue to be important. One early example of 
this was the baker’s yeast reduction of diethyl α-methyl-β-
keto phosphonate.[61] Although the enantioselectivity was 
high (99% ee), the approach suffered from limited diaste-
reoseletivity. Since then, efforts have been made to mine 
the yeast genome for suitable biocatalysts. Drawing from 
a similar approach used earlier by Stewart, Feske and co-
workers screened 20 enzymes from this library against 
diethyl α-chloro-α-keto phosphonate.[62] The group un-
covered a number of enzymes that could reduce the keto 
phosphonate with ranging (12–95% de) diastereoselectivi-
ties for different products (Scheme 21). However, three en-
zymes were identified as catalyzing the DYRKR with >90% 
de and >99% ee which allowed for a simple asymmetric, 
biocatalytic route into fosfomycin. Using whole cell bak-
er’s yeast, only 18% de was obtained, demonstrating again 
the utility of molecular biology and homology modeling 
in driving the frontiers of biocatalysis. 
Just as phosphonates are emerging as important tar-
gets in asymmetric synthesis, so too are sulfur-containing 
compounds, including sulfides, sulfoxides and sulfones. 
Such functionalities facilitate DYRKR processes by reduc-
ing the pKa
 of adjacent C–H bonds. These functionalities 
also provide useful binding handles for chemical biology 
and may be leveraged to facilitate subsequent carbon-
carbon bond forming reactions. As was the case for other 
substrate classes, early investigations into the reduction 
of sulfur-containing systems focused upon the study of 
native ADH activity in baker’s yeast, as shown in Scheme 
22.[63] While β-keto thioethers appear to be processed via 
simple (non-dynamic) kinetic resolution, β-keto sulfones 
undergo efficient DYRKR under these conditions. However, 
as the ring size increases to 7 for cyclic β-keto sulfones, a 
drastic decrease in yield is observed (8%, n=3). 
In a transposed version this system, the sulfone has 
been locked into the cyclic system in the form of 2-ace-
tylsulfolane. The DYRKR still proceeds efficiently provid-
ing the β-hydroxy cyclic sulfone in an overall syn manner 
with high enantioselectivity.[63] 
Interesting sulfur-containing functionalities are found 
in other ADH substrate classes.[64] Earlier, in Scheme 4, for 
example, we illustrated an SNAC thioester reduction cat-
alyzed by a PKS KR. Other examples employing baker’s 
yeast have attempted to reduce an α-alkyl-β-ketoxanthate. 
Surprisingly, this reduction results in increased diastere-
oselectivity (88% de) when compared to the ethyl ester an-
alog (70% de), perhaps due to a more acidic α-proton.[65] 
The common theme to this point is that ADH-medi-
ated DYRKR can be applied to a broad range of keto 
systems, with appropriately acidic α-protons (vide infra). 
The reduction of aldehydes is not normally thought of as 
a stereoselective process (except, perhaps if carried out 
with a deuteride equivalent). However, reductions of al-
Scheme 21. DYRKR of α-alkyl-β-keto phosphonates. 
Scheme 22. DYRKR of β-keto sulfides and sulfones.
Scheme 19. Reduction of β-keto nitriles. 
Scheme 20. Reduction of β-keto nitriles. 
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dehydes with an adjacent stereocenter allow for a DYRKR. 
An early example of such a system was the baker’s yeast-
mediated reduction of a variety of 2-methyl-3-oxopro-
pionates in which the ester chain was systematically 
lengthened.[66] Isobutyl 2-methyl-3-hydroxypropionate 
was obtained in 90% ee (R). This is in good agreement 
with the stereochemistry observed in the reduction of 
2-methyl-3-oxobutanoates in which the (2R,3S) diaste-
reomer predominates. 
This α-alkyl aldehyde-variant of the DYRKR has been 
implemented in the stereoselective reduction of profenals 
in two laboratories recently.[67] Giacomini and co-workers, 
found that HLADH could effect the reduction of 2-phen-
ylpropanal to (S)-2-phenylpropanol in 99% ee. Similar re-
sults were obtained for ibuprofenal. Since then, HLADH 
has also achieved high enantioselectivity in the reduction 
of other profenals.[68] 
Parallel to those studies, a synergistic collaboration be-
tween the Berkowitz laboratory and that of Paul Blum, an 
archaeal microbiologist, led to the identification of a hy-
perthermophilic ADH with great potential for asymmetric 
catalysis. Namely, ADH isozyme 10 from Sulfolobus solfa-
taricus (SsADH-10) was found to selectively mediate the 
DYRKR of a broad set of 2-(S)-profenaldehydes, generat-
ing the corresponding profenols in >94% ee (7 examples, 
Scheme 23).[15c] 
This case also serves to illustrate a potentially impor-
tant feature of hyperthermophilic enzymes in organic syn-
thesis. Namely, in this case, the DYRKR is conducted un-
der essentially “organic solvent-free” conditions; that is, 
in aqueous buffer, containing 5% ethanol as terminal re-
ductant. While the starting (±)-naproxenal substrate is in-
soluble at room temperature, heating to 70 °C both acti-
vates the SsADH-10 enzyme and solubilizes the substrate. 
Thus, heat substitutes for an organic co-solvent. Upon re-
action completion, cooling to room temperature results 
in precipitation of highly enantioenriched (S)-naproxenol, 
allowing for product isolation by simple filtration. The en-
zyme itself, SsADH-10 is recovered in the filtrate and re-
mains efficient even when recycled five times (>94% ee). 
This example illustrates the great potential of thermo-
philic enzymes in stereocontrolled synthesis and/or pro-
cess chemistry, and argues for much greater exploration 
of the enzymology of archaeal hyperthermophiles! 
In summary, a variety of substrate classes have been ex-
plored as platforms for DYRKR. Early discussions focused 
on the importance of a racemizable stereocenter to in-
sure that one has a “dynamic” reductive kinetic resolu-
tion. Indeed, the racemization rate should be fast, relative 
to the enzymatic reduction rate, under the reaction con-
ditions, to ensure an effective DYRKR process. Looking at 
the successful substrates described as a whole, it becomes 
 
 
Scheme 23. DYRKR leading to profenols. 























apparent that most such systems have α-C–H pKa
 values 
between 7.5 and 12.5 (Scheme 24).[59,69] Note that for val-
ues not previously reported in H2O, predicted pKa
 values 
are given here, through application of the program Mar-
vin (version 15.4.2).[70] This “acidity window” is within 2–4 
units of the pH regimes employed for the dehydrogenase-
mediated DYRKR thereby facilitating the rapid racemiza-
tion needed. 
4 Future Challenges 
4.1 More Complex Substrates 
While much of this review has detailed the deployment 
of dehydrogenase enzymes across a battery of carbonyl 
compounds, most commonly bearing an additional acid-
ifying functionality, there is certainly room to increase the 
complexity of such substrates, going forward. This is par-
ticularly true when one considers TurnerIs vision of incor-
porating biocatalytic transformations into standard ret-
rosynthetic analysis. Indeed, given the power of directed 
evolution, along with continuing advances in structural/
computational biology, there will undoubtedly be increas-
ing opportunities to leverage enzymatic chemistry in later 
stages of both process chemistry and natural products 
synthesis. As alluded to earlier, one impressive example 
from pharma field is the latest sitagliptin (Januvia™) pro-
cess from a fruitful Merck/Codexis collaboration, in which 
a transaminase is employed in the late stages to efficiently 
reductively aminate a complex ketone substrate.[9] This 
stellar example of directed evolution and optimization of 
an enzyme toward an advanced synthetic intermediate 
was recognized with the 2010 Presidential Green Chem-
istry Challenge Award. 
Indeed, examples of ADH-mediated DYRKR processes 
with increasingly complex substrates are beginning to ap-
pear. For example, Matsumae and co-workers evaluated a 
number of microorganisms for the ability to reduce a dil-
tiazem precursor.[71] Diltiazen is a calcium channel blocker 
that finds application in the treatment of hypertension 
and arrhythmia. The native ADHs present in baker’s yeast 
were found to efficiently perform DYRKR on this diltia-
zem precursor, reducing the ketone with outstanding di-
astereo- (96% de) and enantioselectivities (>99% ee) in an 
overall 94% yield (Scheme 25). 
It is also incumbent upon the synthetic community to 
continue to challenge dehydrogenase enzymes with sub-
strates presenting new organic functionalities, in order to 
expand the biocatalytic toolbox. One recent such exam-
ple from the Berkowitz laboratory involves the reduction 
of the previously unexplored class of α-fluorinated β-keto 
phosphonates.[15a] Success was had with a Clostridial en-
zyme that had previously shown the ability to generate 
ω-hydroxy esters from the corresponding ω-keto carbox-
ylate esters, in high optical purity. Under DYRKR condi-
tions, a precursor to the taxane side chain was produced 
with high diastereoand enantioselectivity. In an effort to 
expand the substrate repertoire for CaADH, it was chal-
lenged with a variety of α,α-difluoro-β-keto phospho-
nates. Surprisingly, CaADH reduces a large array of keto 
phosphonates with excellent enantioselectivity. This rep-
resents the first example of dehydrogenase application 
to these systems. In this sense, CaADH demonstrates re-
markable active site plasticity, yet retains a high degree of 
stereochemical fidelity. Interestingly, it was also observed 
that the facial selectivity for the reduction is reversed 
upon changing substrate scaffolds from the previously 
employed ω-keto carboxylate substrate (d-selectivity) to 
the more recent β-keto-α,α-difluoro phosphonate ester 
substrates (l-selectivity). 
In an attempt to understand this fascinating behavior, 
computational docking experiments were performed in 
the CaADH active site with a representative β-keto ester, 











Scheme 24. pKa values of various successful DYRKR classes. 
Scheme 25. Reduction of β-substituted-α-keto amides. 
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The results of these experiments are displayed in Scheme 
26. As shown, the keto group for the β- and γ-keto es-
ters are coordinated to S140, a typical binding motif for 
short-chain dehydrogenases.[73] The ester carbonyls for 
the β- and γ-keto ester are shown to be in hydrogen 
bonding distance to Y153 and K207, respectively. How-
ever, the keto phosphonate docks with the keto group 
inverted, forming a hydrogen bond with K207. This ori-
entation leads to the observed stereochemistry for this 
substrate class. Such a result could not have been pre-
dicted, but this example serves to demonstrate the po-
tential of some ADH active sites to exhibit remarkable 
substrate plasticity, while retaining an impressive level 
of stereochemical fidelity. 
4.2 Substrates with Higher pKa Values 
Another challenge on the horizon for the expansion of 
ADH-mediated DYRKR in asymmetric synthesis revolves 
directly around that aforementioned C–H acidity ques-
tion. The acidity of this α-proton limits current DYRKR un-
dertakings to a fairly specific set of substrate classes. As 
was noted above, most of the successful examples cited 
in this review have reported α-C–H pKa
 values between 
7.5 and 12 (Scheme 24), within several pH units of typical 
pH regimes in which ADHs normally operate. One appar-
ent example of this pKa limitation is in the aforementioned 
ADH-mediated reduction of β-keto sulfides and β-keto 
sulfones bearing α-stereocenters (Scheme 22 and accom-
panying discussion). Whereas the latter was found to pro-
vide an excellent DYRKR platform, the former appears to 
be limited to classical kinetic resolution. This result is per-
haps explained through the large differences in acidity of 
the α-proton (Scheme 27).[69a,c] Predicted pKa
 values were 
again obtained using the Marvin program. 
It is important to note that a high pKa
 value can be 
circumvented by a variety of approaches. In the case of 
Scheme 8, exogeneous triethylamine was added to facil-
itate racemization. Another approach is the application 
of enzymes capable of operating in a more basic media, 
either through the use of extremophiles (Scheme 23) or 
through ADH engineering. 
4.3 Substrates with a Third, Non-Dynamic Pre-Exist-
ing Stereocenter 
Another challenge on the horizon will be to uncover bio-
catalysts that are capable of generating three contiguous 
stereocenters. Recall that, while examples have been illus-
trated for such systems (e.g., Scheme 15), only two stereo-
centers were actually set in the biotransformation. In other 
examples, two sequential ADHs were shown to control a to-
tal of three stereocenters. Other such examples exist where 
a third, non-dynamic and also “silent” stereocenter is pres-
Scheme 26. Remarkable active site plasticity exhibited by CaADH: a) d-syn-selectivity with ethyl α-chlorobenzoylacetate; b) d-se-
lectivity seen with γ-keto carboxylate esters; c) l-selectivity seen with a diethyl α,α-difluoro-β-keto phosphonate ester 
Scheme 27. pKa values for some challenging DYRKR classes (the 
dashed box includes “solved” examples).  
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ent prior to the DYRKR. In these cases, the dynamic reduc-
tion proceeds in a highly selective manner. However, the 
non-dynamic center results in two major diastereomeric 
products (Scheme 28).[63,64] Interestingly, in both cases here, 
two essentially enantiopure diastereomers are obtained, 
yet the reported diastereomeric ratio is not 1:1, nor is the 
overall yield quantitative, as it should be, in the ideal case 
of a “silent” pre-existing stereocenter. It thus appears likely 
in these cases that the pre-existing stereocenter is not “si-
lent,” but rather that the ADH (or ADHs) present act at a dif-
ferential rate upon the two enantiomeric ketone substrates, 
sensing this center in this way. Even so, given sufficient time 
and enzyme, it should have been possible to push these re-
actions to completion to give a 1:1 ratio of the observed 
products. One is left to conclude that either insufficient en-
zyme/reaction time was used or that these conditions do 
in fact lead to the formation of other products, comprising 
the remaining 30–35% of the material. Either way, given the 
power of directed evolution, it should be possible to fine 
tune ADHs in the future to be almost completely .silentI to 
the remote stereocenter for such substrates, or highly se-
lective for that center (see Scheme 15) depending on the 
desired outcome of the process. 
4.4 Substrates with Two Dynamic Stereocenters 
Finally, among the more powerful DYRKR processes to be 
developed in the future would be those in which the dehy-
drogenase is able selectively to act upon a substrate with 
more than one dynamic center. Here, as is often the case 
in synthetic chemistry, inspiration to push the envelope 
in biocatalytic synthesis can be found in the organome-
tallic chemistry literature. Indeed, in one nice such exam-
ple, Zhou and co-workers have recently achieved such a 
feat utilizing Noyori-type asymmetric carbonyl reduction. 
Thus exposure α,α’-disubstituted cyclohexanones to Ru-
catalyzed asymmetric ketone hydrogenation under basic 
DYRKR conditions leads to a remarkable result, in which 
three contiguous stereocenters are simultaneously set in 
one synthetic step.[74] Thus, in the presence of an appro-
priate chiral spirocyclic ligand, racemic α,α’-disubstituted 
cyclohexanones are transformed into essentially one of 
eight possible stereoisomeric α,α’-dialkylcyclohexanols. 
High cis,cis-selectivity (>99%) and high enantioselectivity 
are observed (Scheme 29). Given the remarkable ADH ac-
tive site plasticity that has already been observed,[15a] and 
the power of directed evolution,[7c,12b,23a] a menu of such 
biocatalytic transformations may well be forthcoming in 
the not-too-distant future, in which “double, dynamic re-
ductive kinetic resolutions” are achieved, setting two dif-
ferent dynamic centers, while selectively reducing a cen-
tral carbonyl functionality, all in a single operation.   
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